OIE Reference Laboratory Reports Activities

Activities in 2021

This report has been submitted : 2022-01-13 14:37:14

Name of disease (or topic) for which you are a designated OIE Reference Laboratory:	Glanders
Address of laboratory:	Naumburger Str. 96a 07743 Jena GERMANY
Tel.:	+49-3641 804 2100
Fax:	+49-3641 80 42 28
E-mail address:	heinrich.neubauer@fli.de
Website:	www.fli.de
Name (including Title) of Head of Laboratory (Responsible Official):	Mandy Elschner
Name (including Title and Position) of OIE Reference Expert:	Heinrich Neubauer
Which of the following defines your laboratory? Check all that apply:	Governmental

ToR 1: To use, promote and disseminate diagnostic methods validated according to OIE Standards

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in OIE Manual (Yes/No)	Total number of test performed last year	
Indirect diagnostic tests		Nationally	Internationally
CFT	Yes	3	7
Immunoblot	yes	0	7
ELISA-GLANDA	yes	0	2
Direct diagnostic tests		Nationally	Internationally
PCR	yes		9

ToR 2: To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards.
To store and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease.

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by the OIE?

No

3. Did your laboratory supply standard reference reagents (non OIE-approved) and/or other diagnostic reagents to OIE Member Countries?

No

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to OIE Member Countries?

No

ToR 3: To develop, standardise and validate, according to OIE Standards, new procedures for diagnosis and control of the designated pathogens or diseases

6. Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease?

No

7. Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease?

No

ToR 4: To provide diagnostic testing facilities, and, where appropriate, scientific and technical advice on disease control measures to OIE Member Countries

8. Did your laboratory carry out diagnostic testing for other OIE Member Countries?

Yes

Name of OIE Member Country seeking assistance	Date (month)	No. samples received for provision of diagnostic support	No. samples received for provision of confirmatory diagnoses
BELGIUM	April	2	0
CANADA	October	1	0
MONGOLIA	Januar	13	0

9. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country?

No

ToR 5: To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations

10. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own?

Yes

Title of the study	Duration	Purpose of the study	Partners (Institutions)	OIE Member Countries involved other than your country
Validation of Immunoblot	6 month	Validation of Immunoblot	United States Department of Agriculture	UNITED STATES OF AMERICA
Validation of reference sample status	2 month	Validation of reference sample status	Canadian Food Inspection Agency	CANADA

ToR 6: To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases

11. Did your Laboratory collect epizootiological data relevant to international disease control?

No

If the answer is no, please provide a brief explanation of the situation:
no data were collected

12. Did your laboratory disseminate epizootiological data that had been processed and analysed?

Yes

If the answer is yes, please provide details of the data collected:
Validation of GLANDA-ELISA

13. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category)

a) Articles published in peer-reviewed journals: 1
Singha H, Elschner MC, Malik P, Saini S, Tripathi BN, Mertens-Scholz K, Brangsch H, Melzer F, Singh RK, Neubauer H. Molecular Typing of Burkholderia mallei Isolates from Equids with Glanders, India. Emerg Infect Dis. 2021 Jun;27(6):1745-1748. doi: 10.3201/eid2706.203232. PMID: 34013856; PMCID: PMC8153868

Elschner MC, Melzer F, Singha H, Muhammad S, Gardner I, Neubauer H: Validation of a Commercial Glanders ELISA as an Alternative to the CFT in International Trade of Equidae. Frontiers in Veterinary Scienc 2021, 8(62).

P. Kostoulas (1) *, I.A. Gardner (2), M.C. Elschner (3), M.J. Denwood (4), E. Meletis (1), S.S. Nielsen (4) Examples of proper reporting for diagnostic accuracy evaluation (stage-2 validation) of tests for OIE-listed diseases; OIE Volume 40 (1) of the OIE Scientific and Technical Review (‘Diagnostic test validation science: a key element for effective detection and control of infectious animal diseases’).

b) International conferences: 1

Online-Workshop of EU-Reference Laboratory Presentation Mandy Elschner: Validation of a commercial glanders ELISA as an alternative to the CFT in international trade of equidae, 16.11.2021

c) National conferences: 1
Online- AVID-Themenabend: Presentation: Rotz beim Pferd – Klinik, Pathologie und diagnostische Herausforderungen, 01.10.2021

d) Other:
(Provide website address or link to appropriate information) 0

ToR 7: To provide scientific and technical training for personnel from OIE Member Countries
To recommend the prescribed and alternative tests or vaccines as OIE Standards

14. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?

No

ToR 8: To maintain a system of quality assurance, biosafety and biosecurity relevant for the pathogen and the disease concerned

15. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)
DIN EN ISO 17025:2018	Akkreditierungsurkunde_FLI-Riems-Jena_2019.pdf

16. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
microbiology; serology;molecular diagnosis	DAkkS

17. Does your laboratory maintain a “biorisk management system” for the pathogen and the disease concerned?

Yes

(See Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, Chapter 1.1.4)

ToR 9: To organise and participate in scientific meetings on behalf of the OIE

18. Did your laboratory organise scientific meetings on behalf of the OIE?

No

19. Did your laboratory participate in scientific meetings on behalf of the OIE?

No

ToR 10: To establish and maintain a network with other OIE Reference Laboratories designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results

20. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?

Yes

21. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests?

Yes

Purpose of the proficiency tests: [1]	Role of your Reference Laboratory (organiser/ participant)	No. participants	Participating OIE Ref. Labs/ organising OIE Ref. Lab.
Validation of reference serum	participant	4	ANSES

[1] *validation of a diagnostic protocol: specify the test; quality control of vaccines: specify the vaccine type, etc.*

22. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Yes

Title of the project or contract	Scope	Name(s) of relevant OIE Reference Laboratories
providing of control serum for Validation of tests	glanders serodiagnosis	CVRL, ANSES
testing of potential control sera	glanders serodiagnosis	CVRL, ANSES

ToR 11: To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results

23. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease?

Yes

Note: See Interlaboratory test comparisons in: Laboratory Proficiency Testing at: http://www.oie.int/en/our-scientific-expertise/reference-laboratories/proficiency-testing see point 1.3

Purpose for inter-laboratory test comparisons[1]	No. participating laboratories	Region(s) of participating OIE Member Countries
PCR_1	18	☐Africa ☐Americas ☐Asia and Pacific ☒Europe ☐Middle East
CFT_1	26	☐Africa ☐Americas ☐Asia and Pacific ☒Europe ☐Middle East
Isolation	20	☐Africa ☐Americas ☐Asia and Pacific ☒Europe ☐Middle East
CFT_2	15	☐Africa ☐Americas ☐Asia and Pacific ☒Europe ☐Middle East
PCR_2	20	☐Africa ☐Americas ☐Asia and Pacific ☒Europe ☐Middle East

ToR 12: To place expert consultants at the disposal of the OIE

24. Did your laboratory place expert consultants at the disposal of the OIE?

No

25. Additional comments regarding your report: